Journal: Oral oncology

Article Title: The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment

doi: 10.1016/j.oraloncology.2016.08.001

Figure Lengend Snippet: Active clinical trials in recurrent/metastatic head and neck squamous cell carcinoma patients which target the PD-1:PD-L1 pathway. a

Article Snippet: I , PD-L1 , Atezolizumab (MPDL3280A) + CPI-444 (adenosine-A2A receptor target) , Corvus/Genentech , {"type":"clinical-trial","attrs":{"text":"NCT02655822","term_id":"NCT02655822"}} NCT02655822.

Techniques: Clinical Proteomics

Journal: Oral oncology

Article Title: The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment

doi: 10.1016/j.oraloncology.2016.08.001

Figure Lengend Snippet: Monoclonal antibodies targeting the PD-1:PD-L1 pathway.

Article Snippet: I , PD-L1 , Atezolizumab (MPDL3280A) + CPI-444 (adenosine-A2A receptor target) , Corvus/Genentech , {"type":"clinical-trial","attrs":{"text":"NCT02655822","term_id":"NCT02655822"}} NCT02655822.

Techniques: Bioprocessing

Journal: Cell Death & Disease

Article Title: C9-ALS/FTD-linked proline–arginine dipeptide repeat protein associates with paraspeckle components and increases paraspeckle formation

doi: 10.1038/s41419-019-1983-5

Figure Lengend Snippet: a The number of EGFP- or EGFP-FLAG-PR100 (EGFP-F-PR100)-expressing paraspeckle-positive NSC34 cells in RNA FISH assay was counted (100 cells/count). The data are presented as means ± SD ( N = 3). Statistical analysis was performed by the unpaired t -test. b, c NSC-34 cells were infected with indicated adenovirus vectors at a multiplicity of infection (MOI) of 800. At 48 h after the infection, the quantitative real-time PCR analysis of NEAT1 was performed ( b ). The cell lysates were subjected to dot blotting analysis using indicated antibodies ( c ). The data are presented as means ± SD ( N = 3). Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by the Dunnett’s multi comparisons test. d , e Primary cultured cerebral cortical neurons (PCNs) were infected with adenovirus encoding FLAG-PR100 at MOIs of 0–200. To keep the constant total MOIs of adenoviruses, appropriate MOIs of LacZ-encoding adenovirus were added for each infection. At 120 h after the infection, the quantitative real-time PCR analysis of NEAT1 was performed ( d ). The cell lysates were subjected to dot blotting analysis using indicated antibodies ( e ). The data are presented as means ± SD ( N = 3). Statistical analysis was performed by one-way ANOVA followed by the Dunnett’s multi comparisons test. f NSC-34 cells were transfected with the NEAT1 -promoter (+) or NEAT1 -promoterless (−) luciferase vector together with the pEF1-Myc/His-vec (−) or the pEF1-FLAG-PR100 (+). At 48 h after the transfection, the luciferase activity was measured. The data are presented as means ± SD ( N = 3). Statistical analysis was performed by one-way ANOVA followed by the Tukey’s multi comparisons test. g , h NSC-34 cells were infected with adenovirus encoding LacZ or mouse NEAT1_1 at an MOI of 1. Cells were also co-infected with adenovirus encoding LacZ or FLAG-PR100 at an MOI of 200 together with adenovirus encoding LacZ (−) or Cre-recombinase (+) at an MOI of 40. At 48 h after the infection, the quantitative real-time PCR analysis of NEAT1 was performed ( g ). The cell lysates were subjected to dot blotting analysis using indicated antibodies ( h ). The data are presented as means ± SD ( N = 3). Statistical analysis was performed by one-way ANOVA followed by the Dunnett’s multi comparisons test. i , j NSC-34 cells were transfected with 0.2 μg/well of the pCMV-GFP or -mouse NEAT1_2 on 6-well plate. After the transfection, NSC-34 cells were infected with adenovirus encoding FLAG-PR100 at an MOI of 200. Total adenoviruses infected were adjusted at an MOI of 400 with adenovirus encoding LacZ. At 48 h after the infection, the quantitative real-time PCR analysis of NEAT1 was performed ( i ). The cell lysates were subjected to dot blotting analysis using indicated antibodies ( j ). The data are presented as means ± SD ( N = 3). Statistical analysis was performed by one-way ANOVA followed by the Dunnett’s multi comparisons test. k , l NSC-34 cells were infected with adenovirus encoding LacZ or FLAG-PR100 at an MOI of 800. At 48 h after the infection, the quantitative real-time PCR analysis of NEAT1, Nfkb1, and Nr4a1 was performed ( k ). The cell lysates were subjected to dot blotting analysis using indicated antibodies ( l ). The data are presented as means ± SD ( N = 3). Statistical analysis was performed by the unpaired t -test. m–o HeLa cells were infected with adenovirus encoding LacZ or FLAG-PR100 at an MOI of 800. At 48 h after the infection, the cell viability was detected by WST-8 assay ( m ). The cell lysates were subjected to dot blotting analysis using indicated antibodies ( n ). The quantitative real-time PCR analysis of NEAT1, CCL5, CXCL8, SH3PXD2A, and TSHZ2 was performed ( o ). The data are presented as means ± SD ( N = 3). Statistical analysis was performed by the unpaired t -test

Article Snippet: Assay IDs of Taqman probes for mouse Neat1, Neat1_2, Hnrnpm, Nfkb1, Nr4a1, and Gapdh are Mm03942186_s1, AJT96WW (Custom Plus TaqMan® RNA Assays), Mm00513070_m1, Mm00476361_m1, Mm01300401_m1, and Mm99999915_g1, respectively.

Techniques: Expressing, Infection, Real-time Polymerase Chain Reaction, Cell Culture, Transfection, Luciferase, Plasmid Preparation, Activity Assay

Journal: PLoS ONE

Article Title: Androgen-Regulated Transcriptional Control of Sialyltransferases in Prostate Cancer Cells

doi: 10.1371/journal.pone.0031234

Figure Lengend Snippet: (A) LNCap cells were transfected with either scrambled RNA or RelB siRNA and incubated for 120 h with or without 100 nM testosterone. Protein extracts were prepared using RIPA lysis buffer, and the RelB expression level of each sample was analyzed by a Western blot analysis. The expression relative to β-actin is shown in each lane after normalizing the values to the expression level of the scrambled RNA–transfected and testosterone-untreated cells. (B) LNCap cells were transfected with the either scrambled RNA or RelB siRNA and incubated for 120 h with or without 100 nM testosterone. The quantitative real-time PCR analyses for ST3Gal I and II were performed, and the expression levels are reported as the means ± S.E. (n = 3) of the fold difference in mRNA after normalizing the values to the expression level of the scrambled RNA–transfected and testosterone-untreated cells. *P<0.05, **P<0.001.

Article Snippet: Real-time quantitative PCR was performed with an Applied Biosystems 7900 HT Fast Real-Time PCR system under the following conditions: 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Mixtures of probes and primer pairs specific for human ST3Gal I (Hs00161688_m1), ST3Gal II (Hs00199480_m1), ST3Gal VI (Hs00196086_m1), RelB (Hs00232399_m1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Hs99999905_m1) were purchased from Applied Biosystems.

Techniques: Transfection, Incubation, Lysis, Expressing, Western Blot, Real-time Polymerase Chain Reaction

Journal: Clinical Medicine Insights. Oncology

Article Title: Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges

doi: 10.1177/11795549221099869

Figure Lengend Snippet: Summary of clinical trials assessing PD-L1 inhibitors in TNBC management published to date.

Article Snippet: Schmid et al , IMpassion130 Phase 3 , Untreated, locally advanced or mTNBC, ECOG ⩽ 1 , 55 (46-64) , Atezolizumab 840 mg Q2W + Nab-PC (n = 451) , OS 21 m (95% CI: 19-22.6) , PFS 7.2 m (95% CI: 5.6-7.4) , .

Techniques: Clinical Proteomics

Journal: Clinical Medicine Insights. Oncology

Article Title: Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges

doi: 10.1177/11795549221099869

Figure Lengend Snippet: Summary of the ongoing clinical trials assessing PD-L1 inhibitors in TNBC management.

Article Snippet: Schmid et al , IMpassion130 Phase 3 , Untreated, locally advanced or mTNBC, ECOG ⩽ 1 , 55 (46-64) , Atezolizumab 840 mg Q2W + Nab-PC (n = 451) , OS 21 m (95% CI: 19-22.6) , PFS 7.2 m (95% CI: 5.6-7.4) , .

Techniques: Clinical Proteomics, Adjuvant, Mutagenesis

Journal: Journal of Translational Medicine

Article Title: mRNA vaccines in the context of cancer treatment: from concept to application

doi: 10.1186/s12967-024-06033-6

Figure Lengend Snippet: Representative clinical trials of mRNA cancer vaccines encoding TSAs

Article Snippet: BioNTech SE* , BNT122 , 20 epitopes , Lipo-MERIT, i.v. , Atezolizumab , Advanced or metastatic tumors , I , 03289962.

Techniques: Clinical Proteomics, Vaccines, Formulation, Immunopeptidomics